107
Participants
Start Date
September 27, 2018
Primary Completion Date
January 13, 2022
Study Completion Date
January 13, 2022
DE-117 Ophthalmic Solution
Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
NYU Langone Health Department of Ophthalmology, New York
Rochester Ophthalmological Group, PC, Rochester
South Shore Eye Center, Wantagh
Cornerstone Health Care, High Point
Mundorf Eye Center, Charlotte
Asheville Eye Associates, PLLC, Asheville
Glaucoma Consultants and Center for Eye Research, PA, Mt. Pleasant
Coastal Research Associates, LEC, Roswell
Clayton Eye Clinical Research, LLC, Morrow
International Eye Associates, PA, Ormond Beach
Shettle Eye Research, Inc., Largo
Nashville Vision Associates, Nashville
Total Eye Care PA, Memphis
VRF Eye Specialty Group, Memphis
Abrams Eye Center, Cleveland
Apex Eye Clinical Research, LLC, Cincinnati
Comprehensive Eye Care Ltd, Washington
Tekwani Vision Center, St Louis
Heart of America Eye Care, P.A., Shawnee Mission
The Eye Institute, Tulsa
Eye Clinic of Texas, League City
Medical Center Ophthalmology Associates, San Antonio
Texas Eye, PA, Austin
Arizona Eye Center, Chandler
Global Research Management, Glendale
North Valley Eye Medical Group, Mission Hills
Eye Research Foundation, Newport Beach
North Bay Eye Associates, Petaluma
Martel Eye Medical Group, Rancho Cordova
Danbury Eye Physicians & Surgeons, Danbury
Dixon Eye Care, Albany
Scott & Christie and Associates PC, Cranberry Township
Santen Inc.
INDUSTRY